ClinVar Miner

Submissions for variant NM_000089.4(COL1A2):c.3583T>C (p.Cys1195Arg)

dbSNP: rs2115962248
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV002010354 SCV002279113 pathogenic Osteogenesis imperfecta type I; Ehlers-Danlos syndrome, classic type, 1 2022-07-28 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Cys1195 amino acid residue in COL1A2. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL1A2 protein function. ClinVar contains an entry for this variant (Variation ID: 1498972). This missense change has been observed in individual(s) with autosomal dominant osteogenesis imperfecta (PMID: 30715774; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces cysteine, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 1195 of the COL1A2 protein (p.Cys1195Arg).
Laboratorio de Genética Hospitales Universitarios Virgen de las Nieves y Clínico San Cecilio (Granada, Spain), Hospitales Universitarios Virgen de las Nieves y Clínico San Cecilio (Granada, Spain) RCV002259408 SCV002538642 likely pathogenic Osteogenesis imperfecta with normal sclerae, dominant form 2022-06-27 criteria provided, single submitter clinical testing This variant meets the criteria PM2,PP2,PP3 and PP5 according to ACMG (2015)
MGZ Medical Genetics Center RCV002290832 SCV002580050 likely pathogenic Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 2 2022-05-09 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.